Healwell AI Divests Subsidiary in Strategic Refocus

Healwell AI Inc. has taken a decisive step in its corporate evolution by agreeing to sell its subsidiary, HEAL Access Canada. The move, outlined in a non-binding letter of intent signed on March 30, 2026, would see AI Maverick Intel acquire 100% of the unit. This transaction aligns with Healwell's broader strategic pivot to become a pure-play artificial intelligence software provider.

Transaction Terms and Strategic Rationale

Under the proposed terms, Healwell would receive 20 million exchangeable shares of AI Maverick Intel as well as a secured vendor loan of approximately $5.0 million USD. The deal's completion is contingent upon AI Maverick Intel demonstrating a positive net working capital of at least $5.0 million USD at the time of closing. Both parties aim to negotiate and execute a definitive agreement by May 29, 2026.

Concurrently, the companies have amended the terms of an existing right of first refusal agreement. The original provision for 120 million common shares to HEAL Group Holdings has been reduced to 100 million shares.

Should investors sell immediately? Or is it worth buying Healwell AI?

This divestiture follows a period of significant operational momentum for Healwell's core business. For the 2025 fiscal year, the company reported record revenue from continuing operations of about $103.8 million USD—a staggering 427% increase year-over-year. It also achieved its first positive adjusted EBITDA, which came in at $2.3 million USD.

Sharpening the AI Focus

Shedding HEAL Access Canada is designed to sharpen Healwell's operational focus exclusively on its AI-powered clinical decision support and predictive analytics platforms. Management believes this will allow for greater resource allocation and strategic clarity.

Despite these strong financial results and strategic repositioning, Healwell's equity has faced considerable pressure since the start of the year, trading well below its 200-day moving average.

If finalized as scheduled by late May, the transaction will enable AI Maverick Intel to leverage HEAL Access Canada as a foundation for localized health technology services across North America. Meanwhile, Healwell AI is poised to intensify its market profile as a specialized AI platform company, having streamlined its asset portfolio to concentrate solely on its high-growth software segments.

Ad

Healwell AI Stock: New Analysis - 31 March

Fresh Healwell AI information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Healwell AI analysis...

CA42249X1006 | HEALWELL | boerse | 69033832 |